11月26日,在美国临床阶段生物制药公司Poseida Therapeutics Inc.盘中股价飙升224.65%,引发市场广泛关注。分析人士认为,此轮大涨的主因系瑞士制药巨头罗氏公司宣布将斥资15亿美元收购该公司所致。
根据消息,罗氏计划以每股9美元的现金价格收购Poseida Therapeutics,使该公司的总股本价值达到10亿美元。如果达成特定的里程碑,Poseida股东还将额外获得每股4美元的或有价值权,将使整体交易价值最高可达15亿美元。双方目前预计,此笔收购交易将于2025年第一季度完成。
自2022年起,Poseida Therapeutics就与罗氏开展合作,共同为血液系统恶性肿瘤患者开发即用型CAR-T细胞疗法。这次收购将进一步加强双方在同种异体细胞疗法领域的全面合作。分析人士认为,凭借罗氏在产品开发和商业化方面的全球实力,此次交易必将推动CAR-T细胞疗法向全球患者快速普及。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.